Altimmune appoints richard eisenstadt as chief financial officer

Gaithersburg, md., dec. 13, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today announced the appointment of richard eisenstadt as chief financial officer, effective december 31, 2021. mr. eisenstadt succeeds will brown, who is leaving altimmune to pursue other opportunities.
ALT Ratings Summary
ALT Quant Ranking